Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01450982 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT01450982 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01450982, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effects of JNJ-38518168 on the pharmacokinetics (how the body handles a drug) of methotrexate in participants with rheumatoid arthritis.

Interventions

  • DRUG JNJ-38518168 / MTX

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-06
Est. Completion 2011-10
Phase Phase 1

What the Registry Record Tells You About NCT01450982

The ClinicalTrials.gov registry entry for NCT01450982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which JNJ-38518168 / MTX is the first listed.

NCT01450982 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01450982 about?

NCT01450982 is a clinical study titled "A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants". The purpose of this study is to evaluate the effects of JNJ-38518168 on the pharmacokinetics (how the body handles a drug) of methotrexate in participants with rheumatoid arthritis.

What is the current status of trial NCT01450982?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-06. Estimated completion is 2011-10.

What interventions are being tested in trial NCT01450982?

The interventions under investigation include: JNJ-38518168 / MTX (DRUG).

Who is sponsoring clinical trial NCT01450982?

This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.